Welcome to the LeBauer Research Foundations website.
The LeBauer Cardiovascular Research Foundation is a nonprofit organization located at LeBauer HealthCare and Moses H. Cone Memorial Hospital in Greensboro, NC and created to promote clinical research in cardiovascular medicine. While our research is conducted in the Greensboro community, we collaborate with numerous centers in the United States and around the world.
The LeBauer Charitable Research Foundation is a nonprofit organization dedicated to providing financial support for the Cardiovascular Research Foundation. Our mission is to promote cardiovascular research in our community and to improve the cardiovascular health of our community.
Latest News
Dr. Dan Bensimhon Begins
Presidency of Research Foundation
After 17 years as President of the LeBauer Cardiovascular Research Foundation, Dr. Bruce Brodie will turn over leadership responsibilities to Dr. Dan Bensimhon on July 1st. Dr. Brodie will remain Chairman of the Board of Directors of the Foundation. Click to continue...
Dr Joe LeBauer Retires After 41 Years of Distinguished Service and Leadership in Our Community
It is bittersweet that Dr Joe LeBauer, our own "Dr. Joe", will be retiring from cardiology practice and LeBauer HealthCare after more than 40 years as a health care leader in our community. Dr Joe will be remembered by his friends and colleagues, the staff at LeBauer
HealthCare and Moses Cone Hospital, and his patients for his warm and caring
manner and his total dedication to his patients. More than anything, he has been
an unrelenting fierce advocate for his patients. Click to continue...
HORIZONS Trial Finds Superior Outcomes with Bivalirudin in STEMI Patients Treated with Primary PCI
October 2007 Dr. Gregg Stone from the Cardiovascular Research Foundation reported the 30 day results from the HORIZONS Trial at the annual TCT meeting in Washington, DC. Patients with ST-elevation MI (STEMI) undergoing primary PCI were randomized to anticoagulation with heparin + glycoprotein IIb/IIIa platelet inhibitors versus bivalirudin, a direct thrombin inhibitor (Angiomax, the Medicines Company). The primary endpoints were significantly better with bivalirudin --with lower rates of major bleeding and NACE (net adverse clinical events = MACE + major bleeding). MACE (death, re-infarction, urgent TVR and stroke) rates were similar, but there was a strong trend for less mortality with bivalirudin (Table). The LeBauer Cardiovascular Research Foundation was the leading U.S. enroller in the trial and Dr. Bruce Brodie, our local principal investigator, was on the Steering Committee for the trial. Sally Milks, RN, Debbie Gettinger, RN and Vivian Garman, RN were our clinical coordinators. Click to continue...
Dr. Dan Bensimhon Begins
Presidency of Research Foundation
After 17 years as President of the LeBauer Cardiovascular Research Foundation, Dr. Bruce Brodie will turn over leadership responsibilities to Dr. Dan Bensimhon on July 1st. Dr. Brodie will remain Chairman of the Board of Directors of the Foundation. Click to continue...
Dr Joe LeBauer Retires After 41 Years of Distinguished Service and Leadership in Our Community
It is bittersweet that Dr Joe LeBauer, our own "Dr. Joe", will be retiring from cardiology practice and LeBauer HealthCare after more than 40 years as a health care leader in our community. Dr Joe will be remembered by his friends and colleagues, the staff at LeBauer
HealthCare and Moses Cone Hospital, and his patients for his warm and caring
manner and his total dedication to his patients. More than anything, he has been
an unrelenting fierce advocate for his patients. Click to continue...HORIZONS Trial Finds Superior Outcomes with Bivalirudin in STEMI Patients Treated with Primary PCIOctober 2007 Dr. Gregg Stone from the Cardiovascular Research Foundation reported the 30 day results from the HORIZONS Trial at the annual TCT meeting in Washington, DC. Patients with ST-elevation MI (STEMI) undergoing primary PCI were randomized to anticoagulation with heparin + glycoprotein IIb/IIIa platelet inhibitors versus bivalirudin, a direct thrombin inhibitor (Angiomax, the Medicines Company). The primary endpoints were significantly better with bivalirudin --with lower rates of major bleeding and NACE (net adverse clinical events = MACE + major bleeding). MACE (death, re-infarction, urgent TVR and stroke) rates were similar, but there was a strong trend for less mortality with bivalirudin (Table). The LeBauer Cardiovascular Research Foundation was the leading U.S. enroller in the trial and Dr. Bruce Brodie, our local principal investigator, was on the Steering Committee for the trial. Sally Milks, RN, Debbie Gettinger, RN and Vivian Garman, RN were our clinical coordinators. Click to continue...
